Literature DB >> 21632817

Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Eduardo Pimenta1, Richard D Gordon, Ashraf H Ahmed, Diane Cowley, Rodel Leano, Thomas H Marwick, Michael Stowasser.   

Abstract

CONTEXT: Animal studies have demonstrated that dietary sodium intake is a major influence in the pathogenesis of aldosterone-induced effects in the heart such as left ventricular (LV) hypertrophy and fibrosis. LV hypertrophy is an important predictor for cardiovascular morbidity and mortality.
OBJECTIVE: We aimed to investigate the relationships between aldosterone and dietary salt and LV dimensions in patients with primary aldosteronism (PA). DESIGN AND PARTICIPANTS: This case-control study included 21 patients with confirmed PA and 21 control patients with essential hypertension matched for age, gender, duration of hypertension, and 24-h systolic and diastolic blood pressure. MAIN OUTCOME MEASURES: Patients were evaluated by echocardiography and 24-h urinary sodium (UNa) excretion while consuming their usual diets.
RESULTS: Patients with PA had significantly greater mean LV end-diastolic diameter, interventricular septum and posterior wall thicknesses, LV mass (LVM) and LV mass index, and end systolic and diastolic volumes than control patients. UNa significantly positively correlated with interventricular septum, posterior wall thicknesses, and LVM in the patients with PA but not in control patients. In a multivariate analysis, UNa was an independent predictor for LV wall thickness and LV mass among the patients with PA but not in patients with essential hypertension.
CONCLUSIONS: These findings emphasize the importance of dietary sodium in determining the degree of cardiac damage in those patients with PA, and we suggest that aldosterone excess may play a permissive role. In patients with PA, because a high-salt diet is associated with greater LVM, dietary salt restriction might reduce cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632817      PMCID: PMC3167670          DOI: 10.1210/jc.2011-0354

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  41 in total

1.  Salt and aldosterone: a concert of bad effects.

Authors:  Maria Czarina Acelajado; Eduardo Pimenta; David A Calhoun
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Another major role for dietary sodium reduction: improving blood pressure control in patients with resistant hypertension.

Authors:  Lawrence J Appel
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

3.  Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone.

Authors:  Yu Jin; Tatiana Kuznetsova; Marc Maillard; Tom Richart; Lutgarde Thijs; Murielle Bochud; Marie-Christine Herregods; Michel Burnier; Robert Fagard; Jan A Staessen
Journal:  Hypertension       Date:  2009-07-06       Impact factor: 10.190

4.  Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.

Authors:  Krishna Gaddam; Cecilia Corros; Eduardo Pimenta; Mustafa Ahmed; Thomas Denney; Inmaculada Aban; Seidu Inusah; Himanshu Gupta; Steven G Lloyd; Suzanne Oparil; Ahsan Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

5.  Projected effect of dietary salt reductions on future cardiovascular disease.

Authors:  Kirsten Bibbins-Domingo; Glenn M Chertow; Pamela G Coxson; Andrew Moran; James M Lightwood; Mark J Pletcher; Lee Goldman
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.

Authors:  Eduardo Pimenta; Krishna K Gaddam; Suzanne Oparil; Inmaculada Aban; Saima Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

Review 7.  Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.

Authors:  James R Sowers; Adam Whaley-Connell; Murray Epstein
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension.

Authors:  Eduardo Pimenta; Krishna K Gaddam; Monique N Pratt-Ubunama; Mari K Nishizaka; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

Review 10.  Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies.

Authors:  Pasquale Strazzullo; Lanfranco D'Elia; Ngianga-Bakwin Kandala; Francesco P Cappuccio
Journal:  BMJ       Date:  2009-11-24
View more
  23 in total

Review 1.  Primary aldosteronism in 2011: Towards a better understanding of causation and consequences.

Authors:  Michael Stowasser
Journal:  Nat Rev Endocrinol       Date:  2011-12-13       Impact factor: 43.330

Review 2.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

Review 3.  Aldosterone in heart disease.

Authors:  Anastasia S Mihailidou
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

4.  Resistant hypertension: incidence, prevalence, and prognosis.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

Review 5.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 6.  Left heart morphology and function in primary aldosteronism.

Authors:  Alberto Milan; Corrado Magnino; Ambra Fabbri; Michela Chiarlo; Giulia Bruno; Isabel Losano; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-03-01

7.  Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism.

Authors:  Eduardo Pimenta; Michael Stowasser; Richard D Gordon; Susan M Harding; Michel Batlouni; Bin Zhang; Suzanne Oparil; David A Calhoun
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

8.  The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.

Authors:  Chin-Chi Kuo; Poojitha Balakrishnan; Yenh-Chen Hsein; Vin-Cent Wu; Shih-Chieh Jeff Chueh; Yung-Ming Chen; Kwan-Dun Wu; Ming-Jiuh Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-07-16       Impact factor: 1.636

Review 9.  Cardiovascular and renal complications in patients with resistant hypertension.

Authors:  Elizabeth S Muxfeldt; Fabio de Souza; Victor S Margallo; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

10.  Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism.

Authors:  Kaoru Yamashita; Satoshi Morimoto; Yasufumi Seki; Daisuke Watanabe; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2019-08-13       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.